1.30
price down icon4.41%   -0.06
after-market Handel nachbörslich: 1.28 -0.02 -1.54%
loading
Schlusskurs vom Vortag:
$1.36
Offen:
$1.37
24-Stunden-Volumen:
187.85K
Relative Volume:
0.18
Marktkapitalisierung:
$17.17M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-7.51M
KGV:
-0.9848
EPS:
-1.32
Netto-Cashflow:
$-8.02M
1W Leistung:
-2.99%
1M Leistung:
+1.56%
6M Leistung:
-4.41%
1J Leistung:
+21.50%
1-Tages-Spanne:
Value
$1.29
$1.38
1-Wochen-Bereich:
Value
$1.2333
$1.38
52-Wochen-Spanne:
Value
$0.58
$3.80

Hoth Therapeutics Inc Stock (HOTH) Company Profile

Name
Firmenname
Hoth Therapeutics Inc
Name
Telefon
(646)756-2997
Name
Adresse
1177 AVENUE OF THE AMERICAS, NEW YORK, NY
Name
Mitarbeiter
3
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-11
Name
Neueste SEC-Einreichungen
Name
HOTH's Discussions on Twitter

Vergleichen Sie HOTH mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
HOTH
Hoth Therapeutics Inc
1.30 17.96M 0 -7.51M -8.02M -1.32
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2019-10-15 Eingeleitet The Benchmark Company Speculative Buy

Hoth Therapeutics Inc Aktie (HOTH) Neueste Nachrichten

pulisher
Jul 23, 2025

What drives Hoth Therapeutics Inc. stock priceGame-changing returns - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Hoth Therapeutics Inc. Stock Analysis and ForecastHigh-yield trading alerts - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about Hoth Therapeutics Inc. stockConsistent triple returns - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

Is Hoth Therapeutics Inc. a good long term investmentLightning-fast capital gains - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Hoth Therapeutics shares fall 1.52% intraday after signing VA research deal to advance GDNF as breakthrough therapy for obesity and fatty liver. - AInvest

Jul 22, 2025
pulisher
Jul 22, 2025

Hoth Therapeutics partners with VA to test GDNF therapy for obesity By Investing.com - Investing.com South Africa

Jul 22, 2025
pulisher
Jul 22, 2025

Hoth Therapeutics partners with VA to test GDNF therapy for obesity - Investing.com Australia

Jul 22, 2025
pulisher
Jul 22, 2025

New Weight Loss Drug Challenger GDNF Takes On Semaglutide in Landmark VA Obesity Study - Stock Titan

Jul 22, 2025
pulisher
Jul 22, 2025

Why Hoth Therapeutics Inc. stock attracts strong analyst attentionElite Investor Club - Newser

Jul 22, 2025
pulisher
Jul 15, 2025

How Hoth Therapeutics Inc. stock performs during market volatilitySwing Trade Signals - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Hoth Therapeutics Inc. stock price move sharplyDaily Volume Leaders - Newser

Jul 15, 2025
pulisher
Jul 05, 2025

Hoth Therapeutics (NASDAQ:HOTH) Upgraded by Wall Street Zen to Hold Rating - Defense World

Jul 05, 2025
pulisher
Jun 30, 2025

Traumatic Brain Injury Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail

Jun 30, 2025
pulisher
Jun 25, 2025

Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market | Daily Courier - FinancialContent

Jun 25, 2025
pulisher
Jun 24, 2025

Hoth Therapeutics Advances HT-001 for Cancer Treatment - TipRanks

Jun 24, 2025
pulisher
Jun 24, 2025

HT-001's Breakthrough in Oncology Supportive Care: A Game-Changer for Hoth Therapeutics? - AInvest

Jun 24, 2025
pulisher
Jun 24, 2025

Hoth Therapeutics stock rises after positive Phase 2a trial results By Investing.com - Investing.com UK

Jun 24, 2025
pulisher
Jun 23, 2025

Leading Cancer Experts Reveal Phase 2 Data for Revolutionary Skin Toxicity Treatment HT-001 - Stock Titan

Jun 23, 2025
pulisher
Jun 20, 2025

Hoth Therapeutics Regains Nasdaq Compliance on June 18 - TipRanks

Jun 20, 2025
pulisher
Jun 18, 2025

Hoth Therapeutics reports positive preclinical safety data for HT-KIT By Investing.com - Investing.com South Africa

Jun 18, 2025
pulisher
Jun 18, 2025

Hoth Therapeutics Regains Nasdaq Compliance - MarketScreener

Jun 18, 2025
pulisher
Jun 18, 2025

Hoth Therapeutics regains Nasdaq compliance after meeting minimum bid - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Hoth Therapeutics Just Cleared Critical Nasdaq Hurdle: What This Means for Its $1B+ Biotech Pipeline - Stock Titan

Jun 18, 2025
pulisher
Jun 18, 2025

Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT Dose-Dependent Liver Activity with No Observed Toxicity Supports Ind Pathway - MarketScreener

Jun 18, 2025
pulisher
Jun 18, 2025

Hoth Therapeutics reports positive preclinical safety data for HT-KIT - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Hoth Therapeutics (HOTH) Reports Promising Preclinical Outcomes for Cancer Drug | HOTH Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Cancer Drug Breakthrough: Hoth's HT-KIT Achieves Perfect Safety Profile Ahead of Clinical Trials - Stock Titan

Jun 18, 2025
pulisher
Jun 18, 2025

Hoth Therapeutics regains Nasdaq compliance after meeting minimum bid By Investing.com - Investing.com India

Jun 18, 2025
pulisher
Jun 16, 2025

Market Momentum Report: Hoth Therapeutics Inc (HOTH)’s Negative Close at 1.30 - DWinneX

Jun 16, 2025
pulisher
Jun 16, 2025

Hoth Therapeutics Joins 20,000 Biotech Leaders at World's Largest Industry Convention - Stock Titan

Jun 16, 2025
pulisher
Jun 13, 2025

Hoth Therapeutics (HOTH) Secures Patent for HT-KIT Platform in J - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Hoth Therapeutics (NASDAQ:HOTH) Receives “Buy” Rating from D. Boral Capital - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

Hoth Therapeutics secures Japanese patent for mast cell disease treatment By Investing.com - Investing.com South Africa

Jun 12, 2025
pulisher
Jun 12, 2025

Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases - MarketScreener

Jun 12, 2025
pulisher
Jun 12, 2025

Hoth Therapeutics secures Japanese patent for mast cell disease treatment - Investing.com

Jun 12, 2025
pulisher
Jun 12, 2025

Hoth Therapeutics Secures 15-Year Japanese Patent Protection for Revolutionary Mast Cell Disease Platform - Stock Titan

Jun 12, 2025
pulisher
Jun 12, 2025

Hoth Therapeutics (HOTH) Receives 'Buy' Rating from D. Boral Capital | HOTH Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Hoth Therapeutics plans expanded access program for cancer skin toxicity drug - Investing.com India

Jun 12, 2025
pulisher
Jun 11, 2025

Hoth Therapeutics plans expanded access program for cancer skin toxicity drug By Investing.com - Investing.com South Africa

Jun 11, 2025
pulisher
Jun 11, 2025

Hoth Therapeutics, Inc. Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities - MarketScreener

Jun 11, 2025
pulisher
Jun 11, 2025

Hoth Therapeutics Launches Expanded Access Initiative For HT-001 - MarketScreener

Jun 11, 2025
pulisher
Jun 11, 2025

HOTH Seeks Expanded Access for HT-001 to Address Skin Toxicities | HOTH Stock News - GuruFocus

Jun 11, 2025

Finanzdaten der Hoth Therapeutics Inc-Aktie (HOTH)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Kapitalisierung:     |  Volumen (24h):